An Analysis of the Phase III ATLAS Trial in RCC​
August 6th 2014Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses the rationale behind the ATLAS Study, a randomized double-blind phase III study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).